Zalunfiban, a prehospital platelet inhibitor given by injection at the point of first medical contact for suspected STEMI, ...
Researchers are working on microscopic, wireless chips that can travel through the bloodstream and self-implant in a targeted ...
Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...
Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent through less frequent dosing and strong Phase 2 efficacy. APGE's recent $300M fundraising and analyst ...
Hosted on MSN
How Much Should Your Lead Arm Bend When You Swing?
Does your lead arm need to stay straight, or is a little bend okay? In this video, we break down what really happens in the golf swings of top players and why a slight bend might actually help your ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
The Hinds County Sheriff’s Office and Jackson Police Department are investigating an incident that left a man dead early Sunday morning, Oct. 26, after he was shot while sitting in the passenger seat ...
Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. REGN reports third-quarter 2025 results on Oct. 28, 2025. The Zacks ...
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...
LONDON, Oct 24 (Reuters) - Sanofi (SASY.PA), opens new tab reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent, even as the French ...
Sanofi SAN-0.20%decrease; red down pointing triangle said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback